EW Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Edwards Lifesciences Corp (EW) is not a strong buy at this moment for a beginner investor with a long-term strategy. The stock has shown recent price weakness, and while the company has strong revenue growth, its net income and EPS have significantly declined. Additionally, technical indicators and trading signals do not suggest an immediate buying opportunity. Holding off for now is recommended.
The stock is currently showing bearish momentum with a -3.64% regular market change and a -1.69% post-market change. The MACD histogram is negative and expanding downward, indicating bearish momentum. RSI is at 31.801, nearing oversold territory but not yet signaling a reversal. Moving averages are converging, showing no clear trend. The stock is trading near its support level of 75.74, with resistance at 79.22.
Strong Q4 2025 revenue growth of 11.6% YoY and management's raised 2026 earnings guidance.
Positive analyst sentiment from firms like Piper Sandler and Goldman Sachs, citing strong TAVR business performance and potential upside drivers.
Significant decline in net income (-76.35% YoY) and EPS (-75.38% YoY) in Q4
Fiduciary breach investigation by Halper Sadeh LLC, which could impact shareholder confidence.
Recent price target reductions by analysts like Baird and Truist, citing valuation concerns.
In Q4 2025, revenue increased by 13.26% YoY to $1.57 billion, driven by strong TAVR momentum. However, net income dropped by 76.35% YoY to $91.2 million, and EPS fell by 75.38% YoY to $0.16. Gross margin also declined slightly to 78.15%.
Analyst ratings are mixed. While Piper Sandler and Goldman Sachs maintain positive outlooks with price targets of $100 and $95 respectively, others like Baird and Truist have lowered their targets to $87 and $89, citing valuation concerns. The consensus leans towards a cautious stance with some optimism for long-term growth.
